Bruni L, Califano A, De Angelis G, Montagnani A, Pisani M, Pezzarossa G, Pozzo G, Reali D, Rebora A, Zanca A
J Int Med Res. 1980;8(1):1-6. doi: 10.1177/030006058000800101.
In a controlled clinical trial undertaken in ten Italian centres, rifamycin SV was compared to associations of various drugs such as erythromycin, aureomycin, multivitamin preparations, etc, in the treatment of herpes zoster. Up to now 144 patients, suffering from herpes zoster at different localizations, were divided into three groups and randomly given either rifamycin SV by intramuscular injection and topically, or rifamycin SV by injection only, or the routine treatment used at the particular centre in question. To evaluate the effectiveness of the treatments, the presence of subjective and objective symptoms was determined before treatment started and daily thereafter. The duration, in days, of the most important symptoms, such as erythema, vesicles, scabs and pain, was considered for this partial evaluation. All the above-mentioned symptoms constantly showed a shorter duration in the two groups treated with rifamycin SV compared to the group treated with other therapies, with differences as significant on statistical calculation as they were important on the level of a clinical evaluation of the disease's course.
在意大利十个中心进行的一项对照临床试验中，将利福霉素SV与各种药物组合（如红霉素、金霉素、多种维生素制剂等）用于治疗带状疱疹，并进行了比较。截至目前，144名患有不同部位带状疱疹的患者被分为三组，随机给予肌肉注射和局部使用利福霉素SV、仅注射利福霉素SV或相关特定中心使用的常规治疗。为评估治疗效果，在治疗开始前及之后每天确定主观和客观症状的存在情况。在这一局部评估中，考量了最重要症状（如红斑、水疱、结痂和疼痛）的持续天数。与接受其他疗法的组相比，接受利福霉素SV治疗的两组中，上述所有症状的持续时间均持续较短，在统计计算上差异显著，在对疾病病程的临床评估层面也同样显著。
